Showing results (171-180 of 231) with videos related to
Sort By:
Pageof 24
International Journal of Rheumatic Diseases|May 23, 2019
Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and ChinaSeong-Jin Jo, Peter Foley, Stephen Philip Oakley, et al.The Australasian Journal of Dermatology|April 2, 2015
Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological studyLynda Spelman, Diana Rubel, Dedee F Murrell, et al.International Journal of Dermatology|September 11, 2004
A prospective study of the use of cryosurgery for the treatment of actinic keratosesKeng-Ee Thai, Peter Fergin, Michael Freeman, et al.The Journal of Investigative Dermatology|June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 StudyKenneth B Gordon, April W Armstrong, Peter Foley, et al.Journal of Drugs in Dermatology : JDD|April 14, 2021
Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 StudiesMelinda J Gooderham, Boni Elewski, Matthias Augustin, et al.The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.The Australasian Journal of Dermatology|November 23, 2024
Australasian hidradenitis suppurativa management guidelinesJohn Frew, Annika Smith, Pablo Fernandez Penas, et al.Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.The Australasian Journal of Dermatology|August 7, 2018
Psoriasis and infection. A clinical practice narrativeMarius Rademaker, Karen Agnew, Nicholas Anagnostou, et al.Dermatology and Therapy|January 17, 2022
Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA StudyPeter Foley, Tsen-Fang Tsai, Karl Rodins, et al.Pageof 24